Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 10% After Earnings Miss

Posted by Geri Gentry on May 15th, 2026

Shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX – Get Free Report) dropped 10% on Friday after the company announced weaker than expected quarterly earnings. The stock traded as low as $104.69 and last traded at $104.5460. Approximately 98,184 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 317,002 shares. The stock had previously closed at $116.16.

The company reported ($2.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.47).

Analysts Set New Price Targets

INBX has been the subject of several research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Inhibrx Biosciences in a research report on Thursday, January 22nd. Lifesci Capital upgraded shares of Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Stifel Nicolaus initiated coverage on shares of Inhibrx Biosciences in a research report on Wednesday, April 8th. They issued a “buy” rating and a $150.00 target price for the company. Zacks Research upgraded shares of Inhibrx Biosciences to a “hold” rating in a research report on Thursday, April 9th. Finally, Wall Street Zen upgraded shares of Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $150.00.

View Our Latest Research Report on Inhibrx Biosciences

Institutional Investors Weigh In On Inhibrx Biosciences

Large investors have recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd bought a new position in shares of Inhibrx Biosciences during the fourth quarter valued at about $27,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Inhibrx Biosciences by 26.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock worth $56,000 after purchasing an additional 147 shares during the period. Daiwa Securities Group Inc. purchased a new stake in shares of Inhibrx Biosciences during the fourth quarter worth about $66,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Inhibrx Biosciences during the third quarter worth about $40,000. Finally, Diadema Partners LP purchased a new stake in shares of Inhibrx Biosciences during the fourth quarter worth about $103,000. Institutional investors own 82.46% of the company’s stock.

Inhibrx Biosciences Trading Down 9.6%

The company has a quick ratio of 3.93, a current ratio of 3.93 and a debt-to-equity ratio of 12.58. The company has a market capitalization of $1.53 billion, a PE ratio of -11.64 and a beta of 3.88. The stock’s fifty day moving average price is $86.96 and its two-hundred day moving average price is $81.89.

About Inhibrx Biosciences

(Get Free Report)

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.